Pages that link to "Q35930918"
Jump to navigation
Jump to search
The following pages link to Antigenic implications of human immunodeficiency virus type 1 envelope quaternary structure: oligomer-specific and -sensitive monoclonal antibodies (Q35930918):
Displaying 50 items.
- Functional and structural interactions between measles virus hemagglutinin and CD46 (Q24675302) (← links)
- Structure-Based Reverse Vaccinology Failed in the Case of HIV Because it Disregarded Accepted Immunological Theory (Q28071559) (← links)
- Oligomer-specific conformations of the human immunodeficiency virus (HIV-1) gp41 envelope glycoprotein ectodomain recognized by human monoclonal antibodies (Q30436401) (← links)
- Mimotopes selected with antibodies from HIV-1-neutralizing long-term non-progressor plasma (Q33269695) (← links)
- A method for identification of HIV gp140 binding memory B cells in human blood (Q33394829) (← links)
- Preparation of recombinant viral glycoproteins for novel and therapeutic antibody discovery (Q33413784) (← links)
- The role of the viral glycoprotein in HIV-1 persistence. (Q33538298) (← links)
- Protection of rhesus monkeys against infection with minimally pathogenic simian-human immunodeficiency virus: correlations with neutralizing antibodies and cytotoxic T cells (Q33737723) (← links)
- CXCR-4 is expressed by primary macrophages and supports CCR5-independent infection by dual-tropic but not T-tropic isolates of human immunodeficiency virus type 1 (Q33782165) (← links)
- Neutralizing antibodies in sera from macaques infected with chimeric simian-human immunodeficiency virus containing the envelope glycoproteins of either a laboratory-adapted variant or a primary isolate of human immunodeficiency virus type 1. (Q33783516) (← links)
- Stabilization of human immunodeficiency virus type 1 envelope glycoprotein trimers by disulfide bonds introduced into the gp41 glycoprotein ectodomain (Q33784051) (← links)
- Inactivation of human immunodeficiency virus type 1 infectivity with preservation of conformational and functional integrity of virion surface proteins. (Q33784777) (← links)
- Studies of the neutralizing activity and avidity of anti-human immunodeficiency virus type 1 Env antibody elicited by DNA priming and protein boosting (Q33785383) (← links)
- Mapping of epitopes exposed on intact human immunodeficiency virus type 1 (HIV-1) virions: a new strategy for studying the immunologic relatedness of HIV-1. (Q33785510) (← links)
- A recombinant adenovirus-based vector elicits a specific humoral immune response against the V3 loop of HIV-1 gp120 in mice through the "Antigen Capsid-Incorporation" strategy (Q33786140) (← links)
- Modifications that stabilize human immunodeficiency virus envelope glycoprotein trimers in solution (Q33804811) (← links)
- Characterization of stable, soluble trimers containing complete ectodomains of human immunodeficiency virus type 1 envelope glycoproteins (Q33806056) (← links)
- Conserved and exposed epitopes on intact, native, primary human immunodeficiency virus type 1 virions of group M. (Q33809112) (← links)
- Anti-gp41 antibodies cloned from HIV-infected patients with broadly neutralizing serologic activity (Q33826951) (← links)
- Immunogenicity and protective efficacy of oligomeric human immunodeficiency virus type 1 gp140. (Q33835295) (← links)
- Improved elicitation of neutralizing antibodies against primary human immunodeficiency viruses by soluble stabilized envelope glycoprotein trimers (Q33836042) (← links)
- Formaldehyde-treated, heat-inactivated virions with increased human immunodeficiency virus type 1 env can be used to induce high-titer neutralizing antibody responses (Q33911809) (← links)
- Requirements for empirical immunogenicity trials, rather than structure-based design, for developing an effective HIV vaccine (Q34225659) (← links)
- Purification and characterization of oligomeric envelope glycoprotein from a primary R5 subtype B human immunodeficiency virus (Q34332284) (← links)
- High frequency of virus-specific B lymphocytes in germinal centers of simian-human immunodeficiency virus-infected rhesus monkeys (Q34337263) (← links)
- Modifications of the human immunodeficiency virus envelope glycoprotein enhance immunogenicity for genetic immunization (Q34363707) (← links)
- Enhancement of antibodies to the human immunodeficiency virus type 1 envelope by using the molecular adjuvant C3d. (Q34466693) (← links)
- Neutralizing antibody responses in macaques induced by human immunodeficiency virus type 1 monovalent or trivalent envelope glycoproteins (Q34637968) (← links)
- Highly stable trimers formed by human immunodeficiency virus type 1 envelope glycoproteins fused with the trimeric motif of T4 bacteriophage fibritin (Q34999293) (← links)
- Engineering, expression, purification, and characterization of stable clade A/B recombinant soluble heterotrimeric gp140 proteins (Q35666057) (← links)
- Immunization strategies against henipaviruses (Q35735589) (← links)
- Cross-clade neutralization of primary isolates of human immunodeficiency virus type 1 by human monoclonal antibodies and tetrameric CD4-IgG. (Q35849408) (← links)
- Humoral response to oligomeric human immunodeficiency virus type 1 envelope protein. (Q35854300) (← links)
- Effective ex vivo neutralization of human immunodeficiency virus type 1 in plasma by recombinant immunoglobulin molecules (Q35859319) (← links)
- Folding, assembly, and intracellular trafficking of the human immunodeficiency virus type 1 envelope glycoprotein analyzed with monoclonal antibodies recognizing maturational intermediates. (Q35860996) (← links)
- The human immunodeficiency virus type 1 Vif protein modulates the postpenetration stability of viral nucleoprotein complexes (Q35866134) (← links)
- Human immunodeficiency virus type 1 Vif does not influence expression or virion incorporation of gag-, pol-, and env-encoded proteins. (Q35873067) (← links)
- In vitro antigen challenge of human antibody libraries for vaccine evaluation: the human immunodeficiency virus type 1 envelope (Q35874414) (← links)
- Antibody-mediated neutralization of primary isolates of human immunodeficiency virus type 1 in peripheral blood mononuclear cells is not affected by the initial activation state of the cells (Q35879840) (← links)
- Epitope map of human immunodeficiency virus type 1 gp41 derived from 47 monoclonal antibodies produced by immunization with oligomeric envelope protein (Q35880289) (← links)
- Isolation and characterization of monoclonal antibodies elicited by trimeric HIV-1 Env gp140 protein immunogens (Q36103090) (← links)
- A novel assay for antibody-dependent cell-mediated cytotoxicity against HIV-1- or SIV-infected cells reveals incomplete overlap with antibodies measured by neutralization and binding assays (Q36363866) (← links)
- Enhancement of feline immunodeficiency virus (FIV) infection after DNA vaccination with the FIV envelope (Q36549107) (← links)
- Analysis of the interaction of the human immunodeficiency virus type 1 gp120 envelope glycoprotein with the gp41 transmembrane glycoprotein (Q36549220) (← links)
- N-terminal substitutions in HIV-1 gp41 reduce the expression of non-trimeric envelope glycoproteins on the virus (Q36565090) (← links)
- Cross-reactive human immunodeficiency virus type 1-neutralizing human monoclonal antibody that recognizes a novel conformational epitope on gp41 and lacks reactivity against self-antigens (Q36747750) (← links)
- A simple one-step method for the preparation of HIV-1 envelope glycoprotein immunogens based on a CD4 mimic peptide (Q37102810) (← links)
- Elicitation of neutralizing antibodies with DNA vaccines expressing soluble stabilized human immunodeficiency virus type 1 envelope glycoprotein trimers conjugated to C3d. (Q37422543) (← links)
- Limitations to the structure-based design of HIV-1 vaccine immunogens (Q37910841) (← links)
- Basic research in HIV vaccinology is hampered by reductionist thinking (Q38025633) (← links)